Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in Patients with BCG-naive High-Risk NMIBC By Ogkologos - July 22, 2025 605 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CREST study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Tarlatamab Transdermal Oestradiol Patches Non-inferior to LHRH Agonists Regarding Metastasis-Free Survival in Patients with Locally Advanced Prostate Cancer EMA Recommends Extension of Indications for Selpercatinib MOST POPULAR Despite Proven Safety of HPV Vaccines, More Parents Have Concerns October 22, 2021 Breaking News: Medical Debt and Your Credit Report March 23, 2022 One year on: How has COVID-19 affected cancer services? May 14, 2021 Students Invent Disposable Core Biopsy Needle to Make the Procedure Cheaper May 21, 2019 Load more HOT NEWS Addressing Cancer Pain with Complementary Methods (Part 2) Patients with Breast, Colorectal, and Pancreatic Cancers With ATM, CHEK2, or... Clinical Trials in Genitourinary Cancers: TALAPRO-2, KEYNOTE-905, and COSMIC-313 Training Cancer Researchers: A Conversation with Dr. Oliver Bogler
